O-OGC09 PD-1 inhibitors in Oesophageal Cancer: A systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic landscape
نویسندگان
چکیده
Abstract Background Patients with oesophageal or gastro-oesophageal junction (GOJ) cancer that fail to respond chemoradiotherapy have a poor clinical prognosis. Recent trials investigated the use of immune checkpoint inhibitors in these patients. The programmed cell death protein 1 (PD-1) emerged as exciting therapeutic options other solid tumors, such non-small lung cancer, renal carcinoma and melanoma. We assessed efficacy safety PD-1 GOJ cancers. Methods This systematic review was performed accordance Preferred Reporting Items for Systematic Reviews Meta-Analyses (PRISMA) guidelines. A comprehensive electronic literature search from EMBASE, Pubmed, Scopus, MEDLINE Google Scholar databases conducted up April 1st 2021. Results identified nine eligible studies reporting outcomes 2149 patients treated blockade compared 1244 either placebo standard regimen chemotherapy cancer. Clinically significant improvements median overall survival been demonstrated advanced metastatic while maintaining acceptable profiles. Promising data has also recently adjuvant setting. Conclusions delivered impressive benefit whilst remaining well tolerated. Its setting may further advance our treatment this difficult-to-treat tumour, more advancements immunotherapy landscape are highly anticipated. However, characterization PD-1/PD-L1 pathway is required optimise patient selection.
منابع مشابه
PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.
BACKGROUND Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success. An understanding of the checkpoint signaling pathway involving the programmed death 1 (PD-1) receptor and its ligands (PD-L1/2) has clarified the role of these approaches in tumor-induced immune suppression and has been a critical advancement in immunotherapeutic drug...
متن کاملHuman Cancer Immunotherapy with PD-1/PD-L1 Blockade
The ligation of programmed cell death-1 (PD-1) to its ligands PD-L1 and PD-L2 counteracts T-cell activation, which is critical in immune tolerance. The persistent high expression of PD-1 and PD-L1 are also observed on tumor-infiltrating lymphocytes and various tumor cells, maintaining the highly suppressive microenvironment in tumor sites and promoting tumor malignancies. The blockade of PD-1 a...
متن کاملRegulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Immune checkpoint blockades, such as inhibitors against programmed death 1 (PD-1) and its ligand (PD-L1), have received extensive attention in the past decade because of their dramatic clinical outcomes in advanced malignancies. However, both primary and acquired resistance becomes one of the major obstacles, which greatly limits the long-lasting effects and wide application of PD-1/PD-L1 block...
متن کاملEfficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis
Background Programmed cell death 1 (PD-1) and programmed cell death-ligand 1(PD-L1) inhibitors have captured our attention as new therapeutic options for several tumor types. Nonetheless, the differences in efficacy between PD-1/PD-L1 inhibitors and conventional treatments (chemotherapy or targeted therapy) in pretreated advanced cancer patients remain unclear. Materials and Methods A systema...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Surgery
سال: 2021
ISSN: ['1365-2168', '0007-1323']
DOI: https://doi.org/10.1093/bjs/znab429.041